We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
A California appellate court has held that a name-brand drug manufacturer's duty of care in disseminating information about the drug can extend to users of generic versions of that drug
